Rosa Simpson
Non-Executive Chairman
life sciencess
Investiga
Ecuador
Biography
and alliance management of collaborations and partnerships with pharmaceutical companies and universities. He provided business and scientific leadership to drug development programs for the treatment of HIV, Hepatitis B and Hepatitis C, including Sofosbuvir. Prior to Pharmasset, Dr. De La Rosa held both scientific and business positions at Visible Genetics, where he was responsible for the development and improvement of genotyping tests for HIV, Hepatitis B and Hepatitis C, including the first sequencing-based HIV drug resistance test to receive FDA approval. Dr. De La Rosa also held scientific positions at Innogenetics, Boston Biomedica, and Digene, developing molecular diagnostic tests for infectious diseases. He is an inve
Research Interest
and alliance management of collaborations and partnerships with pharmaceutical companies and universities. He provided business and scientific leadership to drug development programs for the treatment of HIV, Hepatitis B and Hepatitis C, including Sofosbuvir. Prior to Pharmasset, Dr. De La Rosa held both scientific and business positions at Visible Genetics, where he was responsible for the development and improvement of genotyping tests for HIV, Hepatitis B and Hepatitis C, including the first sequencing-based HIV drug resistance test to receive FDA approval. Dr. De La Rosa also held scientific positions at Innogenetics, Boston Biomedica, and Digene, developing molecular diagnostic tests for infectious diseases. He is an inve
